Delfi Diagnostics: Jacob Van Naarden

Delfi Diagnostics has appointed Jacob Van Naarden to its board of directors. Van Naarden is senior VP of Eli Lilly and CEO of Loxo@Lilly. He previously served as chief operating officer at Loxo Oncology, which Lilly acquired in 2019. He also previously held positions at HealthCor Management, Aisling Capital, and Goldman Sachs.